ReviewJournal of pharmacopuncture2025
Types and Doses of Pharmacopuncture for Lumbar Disc Herniation: a scoping review of clinical studies.
Review in Journal of pharmacopuncture, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Lumbar disc herniation (LDH) symptoms include lower back pain (LBP), radiating leg pain, and muscle weakness in muscles innervated by the affected nerve roots. The treatment of LDH is divided into conservative and surgical treatments. In this study, we aimed to summarize and analyze the clinical studies of pharmacopuncture (PP) on LDH and to assess its utilization rate in clinical practice. Methods: In this scoping review, we searched both the domestic (Research information sharing service [RISS], SCIENCE ON, online access to shared information system [OASIS]), and international (PubMed) databases to gather case reports, retrospective studies, and randomized controlled trials with information on the types and doses of PP by injection points up to September 3rd, 2024. The information obtained was analyzed using the PP type and dose at each injection point. Results: Sixty-three studies were identified for this study. We observed that bee venom was most used (34 studies), followed by Shinbaro (29 studies). Studies on other PP types did not exceed four each. The PP doses ranged from a minimum of 0.04 cc to a maximum of 6.00 cc. The most used dose was 1.00 cc. Injection points were intradermal at each disc level, Ah-Shi points, tender points, muscles, traditional acupoints, and facet joints. Conclusion: We analyzed variations in injection points and maximum doses of PP according to substance type and anatomical location. These results support the development of standardized protocols for acupoint injection therapy in patients with LDH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.